VasoMedical’s EECP® Therapy Reaches New Level of Acceptance in Russia
EECP® Therapy Training and Research Center Opens in Moscow
November 30, 2012 - WESTBURY, NY Enhanced external counterpulsation (EECP®) Therapy, a proprietary, non-invasive treatment for several heart conditions, created by VasoMedical, Inc., has continued to expand its international footprint in Russia. VasoMedical, Inc., (“VasoMedical” or the “Company”) (OTCQB: VASO) announced today that, through its successful effort with its distributor in Russia, Alimpex, Moscow State University of Medicine and Dentistry (MSUMD) will open a new research and clinical center for EECP® at Tsentrosoyuz Hospital in Moscow on December 5, 2012.
The new center, called the Russian Scientific and Methodological Centre for Clinical Research and Use of Enhanced External Counterpulsation (EECP®), will also provide a special course on EECP® Therapy, designed in accordance with the Russian standards of medical education, as part of the curriculum for all medical students at MSUMD.
“VasoMedical has had a great opportunity to work closely with its distributor Alimpex, and many physicians in Russia who have demonstrated the clinical benefits of EECP® Therapy among their patients,” stated Larry Liebman, Vice President of Sales & Marketing for VasoMedical. “Some of these physicians began using EECP® Therapy more than ten years ago and have witnessed first-hand the consistent improvement in their patients' health, as well as the reduction of medical treatments, hospitalizations and cost.”
Mr. Liebman continued, “These physicians have the foresight to appreciate the role EECP® Therapy can play in treating cardiovascular diseases while reducing costs in an improved healthcare system under the new medical modernization program that Russia has embarked upon. The creation of the Center will ensure that their work continues as well as prepare future physicians to properly use EECP® Therapy for more patients in the future.”
To celebrate the opening of the Center, MSUMD will host an international conference titled “Enhanced External Counterpulsation, New Approach to Endothelial Dysfunction” on December 5, 2012 and continue with the practical applications on December 6, 2012 in the VasoMedical/BIOX/Alimpex EECP® exhibit booth at the Zdravookhraneniye 2012 Health Fair at the Expocentre Fairgrounds in Moscow.
In addition to the Zdravookhraneniye Health Fair in Russia, VasoMedical plans to increase its participation at major national and international meetings and exhibitions in the coming year. This presence will help generate more sales opportunities for its core technology, EECP® Therapy, as well as its BIOX ECG Holter and ambulatory blood pressure monitors and patient management products. The Company already has plans to attend and exhibit at the Arab Health Congress in Dubai, United Arab Emirates, the Medical Fair India 2013 in New Delhi, India and the American College of Cardiology Annual Conference in San Francisco, California.
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.